Basic Information

Gene symbol ADRB2 Synonyms ADRB2R, ADRBR, ARB2, B2AR, BAR, BETA2AR Type of gene protein-coding
Gene perturbation-related omics dataset PertOrg
Description adrenoceptor beta 2

GTO ID GTC0219
Trial ID NCT02250612
Disease Pancreatic Cancer | Melanoma | Renal Cell Carcinoma
Altered gene ADRB2
Therapeutic/Target gene Target gene
TherapysiRNA
Treatment SYL0400129|bamosiran
PhasePhase2
Recruitment statusCompleted
TitleA Phase II, Observer Masked, Active Controlled Study of SYL040012 for the Treatment of Elevated Intraocular Pressure in Patients With Open-angle Glaucoma or Ocular Hypertension
Year2014
CountryEstonia|Germany|Spain|United States
Company sponsorSylentis, S.A.
Other ID(s)SYL040012_IV|2013-002947-27

Clinical Result

Cohort1: SYL040012_dose level 1
Administration route drop
Dosage SYL040012, 0.375%, each eye once daily
Pts 37
Age Adult, Older_Adult
Outcome Change From Baseline in the Mean Diurnal IOP:-2.4
Adverse reactions No serious clinical adverse events
Cohort2: SYL040012_dose level 2
Administration route drop
Dosage SYL040012, 0.750%, each eye once daily
Pts 40
Age Adult, Older_Adult
Outcome Change From Baseline in the Mean Diurnal IOP:-3.2
Adverse reactions No serious clinical adverse events
Cohort3: SYL040012_dose level 3
Administration route drop
Dosage SYL040012, 1.125%, each eye once daily
Pts 37
Age Adult, Older_Adult
Outcome Change From Baseline in the Mean Diurnal IOP:-3.1
Adverse reactions No serious clinical adverse events
Cohort4: SYL040012_dose level 4
Administration route drop
Dosage SYL040012, 1.5%, each eye once daily
Pts 33
Age Adult, Older_Adult
Outcome Change From Baseline in the Mean Diurnal IOP:-3.1
Adverse reactions No serious clinical adverse events
Cohort5: Timolol maleate
Administration route drop
Dosage Timolol maleate, 0.5%, each eye once daily
Pts 37
Age Adult, Older_Adult
Outcome Change From Baseline in the Mean Diurnal IOP:-6.1
Adverse reactions No serious clinical adverse events

Relationship Graph

Overview of Knowledge Graph